Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $7.5 million.

  • Cytosorbents' Cash & Current Investments rose 1593.85% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 1593.85%. This contributed to the annual value of $8.3 million for FY2024, which is 4140.6% down from last year.
  • As of Q3 2025, Cytosorbents' Cash & Current Investments stood at $7.5 million, which was up 1593.85% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Cash & Current Investments ranged from a high of $68.5 million in Q1 2021 and a low of $6.5 million during Q3 2024
  • For the 5-year period, Cytosorbents' Cash & Current Investments averaged around $25.3 million, with its median value being $14.1 million (2023).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 15945.75% in 2021, then crashed by 6305.51% in 2022.
  • Quarter analysis of 5 years shows Cytosorbents' Cash & Current Investments stood at $52.1 million in 2021, then crashed by 57.53% to $22.1 million in 2022, then plummeted by 36.19% to $14.1 million in 2023, then plummeted by 41.41% to $8.3 million in 2024, then dropped by 8.99% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $10.2 million for Q2 2025, and $11.6 million during Q1 2025.